Screen the A10 antibody for off-target binding to plasma membrane proteins and secreted proteins.
Ended Purchase Order Awarded Last action
- Contract number
- 75N91026P00004
- Awardee
-
Charles River Discovery Research Services UK LIMITED UEI KWY4CPWDFNT6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $38,750
Award facts
- Contract value 100% obligated
- $38,750.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Great Britain, United Kingdom
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a $38,750 firm fixed-price purchase order to Charles River Discovery Research Services UK LIMITED on January 28, 2026, for screening the A10 antibody to identify potential off-target binding to plasma membrane proteins and secreted proteins. The work will be performed in Great Britain, United Kingdom, with an ultimate completion date of May 15, 2026. No set-aside designation was used for this contract award.
This engagement supports NCI's research objectives by leveraging Charles River's specialized capabilities in antibody characterization and target validation. Off-target binding screening is a critical component of antibody development and therapeutic validation, helping to ensure specificity and reduce potential adverse effects in future clinical applications. The contract represents a targeted, short-duration engagement focused on delivering specific analytical services to advance cancer research initiatives.
Quick answers
Who was awarded contract 75N91026P00004?
75N91026P00004 was awarded to Charles River Discovery Research Services UK LIMITED by National Cancer Institute (National Institutes of Health) on January 28, 2026.
How much is contract 75N91026P00004 worth?
The government has obligated $38,750 on 75N91026P00004.
Was contract 75N91026P00004 competed?
The extent of competition for 75N91026P00004 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award